Press releases
- Sage Therapeutics to Participate in Upcoming May Investor Conferences
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
Key statistics
On Friday, SAGE Therapeutics Inc (SG7:STU) closed at 10.29, 4.19% above its 52-week low of 9.88, set on May 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.52 |
---|---|
High | 10.52 |
Low | 10.29 |
Bid | 10.04 |
Offer | 10.39 |
Previous close | 9.88 |
Average volume | 40.00 |
---|---|
Shares outstanding | 60.18m |
Free float | 52.68m |
P/E (TTM) | -- |
Market cap | 668.62m USD |
EPS (TTM) | -8.40 USD |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼